Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 2
- Registration Number
- NCT04269850
- Locations
- 🇷🇺
Pavlov First Saint-Petersburg State Medical University, Saint Petersburg, Russian Federation
Actuate 1901: 9-ING-41 in Myelofibrosis
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04218071
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Cancer Center, Augusta, Georgia, United States
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 90
- Registration Number
- NCT04217356
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Oral TP-3654 in Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04176198
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Montefiore Cancer Center, Bronx, New York, United States
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 586
- Registration Number
- NCT04116502
- Locations
- 🇬🇧
Royal United Hospital, Bath, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
🇬🇧Southmead Hospital, Bristol, United Kingdom
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
First Line Therapy for High Risk Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 198
- Registration Number
- NCT04061876
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 14
- Registration Number
- NCT04055844
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Washington University Medical School, Saint Louis, Missouri, United States
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 85
- Registration Number
- NCT04041050
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
🇺🇸City of Hope /ID# 239769, Duarte, California, United States
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT04016116
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.